548 related articles for article (PubMed ID: 33412948)
21. On the continuous (R)evolution of antibody-based and CAR T cell therapies in multiple myeloma: an early 2022 glance into the future.
Sunder-Plassmann V; Aksoy O; Lind J; Pecherstorfer M; Vallet S; Podar K
Expert Opin Pharmacother; 2022 Aug; 23(12):1425-1444. PubMed ID: 35829636
[TBL] [Abstract][Full Text] [Related]
22. BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice.
Zhou X; Rasche L; Kortüm KM; Mersi J; Einsele H
Haematologica; 2023 Apr; 108(4):958-968. PubMed ID: 36263838
[TBL] [Abstract][Full Text] [Related]
23. Quad-class exposed/refractory myeloma is associated with short survival.
Piron B; Costes-Tertrais D; Gastinne T; Fourmont AM; Dubruille V; Blin N; Moreau P; Touzeau C; Tessoulin B
Br J Haematol; 2024 Jan; 204(1):186-190. PubMed ID: 37833834
[TBL] [Abstract][Full Text] [Related]
24. BCMA in Multiple Myeloma-A Promising Key to Therapy.
Kleber M; Ntanasis-Stathopoulos I; Terpos E
J Clin Med; 2021 Sep; 10(18):. PubMed ID: 34575199
[TBL] [Abstract][Full Text] [Related]
25. Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma.
Tacchetti P; Talarico M; Barbato S; Pantani L; Mancuso K; Rizzello I; Zamagni E; Cavo M
Expert Rev Anticancer Ther; 2024 Jun; 24(6):379-395. PubMed ID: 38798125
[TBL] [Abstract][Full Text] [Related]
26. B-Cell Maturation Antigen (BCMA) as a Target for New Drug Development in Relapsed and/or Refractory Multiple Myeloma.
Abramson HN
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32707894
[TBL] [Abstract][Full Text] [Related]
27. "Off-the-shelf" immunotherapies for multiple myeloma.
Mohammed T; Mailankody S
Semin Oncol; 2022 Feb; 49(1):60-68. PubMed ID: 35123801
[TBL] [Abstract][Full Text] [Related]
28. Toxicity Profile of Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapies in Multiple Myeloma: Pathogenesis, Prevention and Management.
Markouli M; Ullah F; Unlu S; Omar N; Lopetegui-Lia N; Duco M; Anwer F; Raza S; Dima D
Curr Oncol; 2023 Jul; 30(7):6330-6352. PubMed ID: 37504327
[TBL] [Abstract][Full Text] [Related]
29. Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety.
Offidani M; Corvatta L; Morè S; Olivieri A
Drug Des Devel Ther; 2021; 15():2401-2415. PubMed ID: 34103900
[TBL] [Abstract][Full Text] [Related]
30. A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma.
Mei H; Li C; Jiang H; Zhao X; Huang Z; Jin D; Guo T; Kou H; Liu L; Tang L; Yin P; Wang Z; Ai L; Ke S; Xia Y; Deng J; Chen L; Cai L; Sun C; Xia L; Hua G; Hu Y
J Hematol Oncol; 2021 Oct; 14(1):161. PubMed ID: 34627333
[TBL] [Abstract][Full Text] [Related]
31. Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma.
Mohan M; Chakraborty R; Bal S; Nellore A; Baljevic M; D'Souza A; Pappas PG; Berdeja JG; Callander N; Costa LJ
Br J Haematol; 2023 Dec; 203(5):736-746. PubMed ID: 37287117
[TBL] [Abstract][Full Text] [Related]
32. Comparison of infectious complications with BCMA-directed therapies in multiple myeloma.
Nath K; Shekarkhand T; Nemirovsky D; Derkach A; Costa BA; Nishimura N; Farzana T; Rueda C; Chung DJ; Landau HJ; Lahoud OB; Scordo M; Shah GL; Hassoun H; Maclachlan K; Korde N; Shah UA; Tan CR; Hultcrantz M; Giralt SA; Usmani SZ; Shahid Z; Mailankody S; Lesokhin AM
Blood Cancer J; 2024 May; 14(1):88. PubMed ID: 38821925
[TBL] [Abstract][Full Text] [Related]
33. An Overview of CAR T Cell Mediated B Cell Maturation Antigen Therapy.
Quazi S
Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):e392-e404. PubMed ID: 34992008
[TBL] [Abstract][Full Text] [Related]
34. Impact of Treatment Modality and Route of Administration on Cytokine Release Syndrome in Relapsed or Refractory Multiple Myeloma: A Meta-Analysis.
Soltantabar P; Sharma S; Wang D; Lon HK; Czibere A; Hickmann A; Elmeliegy M
Clin Pharmacol Ther; 2024 Jun; 115(6):1258-1268. PubMed ID: 38459622
[TBL] [Abstract][Full Text] [Related]
35. Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma.
Choi T; Kang Y
Pharmacol Ther; 2022 Apr; 232():108007. PubMed ID: 34582835
[TBL] [Abstract][Full Text] [Related]
36. Targeting B Cell Maturation Antigen in Patients with Multiple Myeloma: Current Perspectives.
Shrivastava T; Van Rhee F; Al Hadidi S
Onco Targets Ther; 2023; 16():441-464. PubMed ID: 37359353
[TBL] [Abstract][Full Text] [Related]
37. BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma.
Cho SF; Lin L; Xing L; Li Y; Yu T; Anderson KC; Tai YT
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32516895
[TBL] [Abstract][Full Text] [Related]
38. New and emerging pharmacotherapies for the management of multiple myeloma.
Moore DC; Oxencis CJ; Shank BR
Am J Health Syst Pharm; 2022 Jul; 79(14):1137-1145. PubMed ID: 35333922
[TBL] [Abstract][Full Text] [Related]
39. Effective anti-BCMA retreatment in multiple myeloma.
Gazeau N; Beauvais D; Yakoub-Agha I; Mitra S; Campbell TB; Facon T; Manier S
Blood Adv; 2021 Aug; 5(15):3016-3020. PubMed ID: 34351389
[TBL] [Abstract][Full Text] [Related]
40. Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapy in Multiple Myeloma: Moving Into the Future.
Holstein SA; Grant SJ; Wildes TM
J Clin Oncol; 2023 Sep; 41(27):4416-4429. PubMed ID: 37471687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
